Kronos Bio (KRON) said Wednesday that its board has named Deborah Knobelman as president and interim chief executive officer, starting Dec. 3.
Knobelman will succeed Norbert Bischofberger, who will step down Dec. 3 but remain on the board of directors and serve as an advisor, Kronos said.
The company also said it will reduce its workforce by about 83% by the end of year as part of a cost reduction strategy while exploring possible business combinations or sale of preclinical assets.
Kronos Bio shares were rising more than 11% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.